In:
Cancer, Wiley, Vol. 126, No. 16 ( 2020-08-15), p. 3674-3688
Abstract:
The 5‐year results from the NPC‐0501 trial demonstrate that conventional fractionation remains the standard recommendation for patients with locoregionally advanced nasopharyngeal carcinoma who are treated with chemoradiotherapy because acceleration does not appear to achieve any therapeutic benefit, and could affect the potential benefit of changing from concurrent‐adjuvant to induction‐concurrent chemotherapy. For patients who undergo irradiation with conventional fractionation, changing the chemotherapy sequence from concurrent‐adjuvant to induction‐concurrent, particularly using induction cisplatin and capecitabine, could improve efficacy without resulting in the development of late toxicities. However, further validation is needed for confirmation.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v126.16
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink